Skip to main content
. 1999 Jul 1;104(1):5–11. doi: 10.1172/JCI6094

Figure 1.

Figure 1

(a) Levels of immunoreactive Smad7 in the lungs of mice after treatment with bleomycin plus AdCMV-Smad7. Expression of exogenous Smad6 or Smad7 derived from an AdCMV-Smad6 or AdCMV-Smad7 construct was detected in the lungs (lane 1: Smad6; lane 2: Smad7), peripheral blood cells (lane 3: Smad7), and spleen (lane 4: Smad7) of bleomycin-treated mice at day 7 by Western blotting using anti-FLAG antibody after infection of AdCMV-Smad6 or AdCMV-Smad7 at day 0. (b) Quantitative analysis of expression of Smad7 transgene in the lungs of mice after treatment with bleomycin plus AdCMV-Smad7. Expression of Smad7 transgene was detected by Western blotting as shown in a, and intensity of the bands of exogenous Smad7 detected at days 0, 2, 7, 14, and 21 was measured using NIH Image software. The relative intensity of the bands at indicated days was expressed as relative intensity compared with that at day 0. (c) Cellular localization of Smad7 transgene in the lungs of mice after treatment with bleomycin plus AdCMV-Smad7. Immunohistochemical staining using anti-FLAG antibody was performed as described in the text. Staining was observed mainly in the nucleus of alveolar epithelial cells and interstitial fibroblast-like cells (left), and bronchial epithelial cells (right).